Dr. Martins on Managing Toxicities Associated With Lenvatinib in DTC

Renato G. Martins, MD
Published: Thursday, Feb 25, 2016



Renato G. Martins, MD, medical director of Outpatient General Oncology/Hematology at Seattle Cancer Care Alliance, medical director of Thoracic/Head and Neck Oncology, and professor at the University of Washington School of Medicine, discusses side effects that are associated with lenvatinib (Lenvima).

Lenvatinib and sorafenib (Nexavar), both tyrosine kinase inhibitors, are agents used for the treatment of patients with differentiated thyroid cancer (DTC), Martins explains.

While sorafenib may have associated toxicities such as hand-foot syndrome, lenvatinib is associated with mucositis or gastrointestinal events. Martins cautions that these side effects must be proactively managed, citing dose reductions with lenvatinib as a common method.



Renato G. Martins, MD, medical director of Outpatient General Oncology/Hematology at Seattle Cancer Care Alliance, medical director of Thoracic/Head and Neck Oncology, and professor at the University of Washington School of Medicine, discusses side effects that are associated with lenvatinib (Lenvima).

Lenvatinib and sorafenib (Nexavar), both tyrosine kinase inhibitors, are agents used for the treatment of patients with differentiated thyroid cancer (DTC), Martins explains.

While sorafenib may have associated toxicities such as hand-foot syndrome, lenvatinib is associated with mucositis or gastrointestinal events. Martins cautions that these side effects must be proactively managed, citing dose reductions with lenvatinib as a common method.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x